Conditions: HIV Osteopenia Osteoporosis HIV Infections
Keywords: HIV+ Raltegravir Tenofovir osteopenia osteoporosis bone markers treatment experienced
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 52
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if low bone mineral density (a measurement of how thick and strong bones are) improves in adults with HIV infection who switch their HIV medication tenofovir to another HIV medication raltegravir.

Hypothesis:That Bone Mineral Density (BMD) will improve in osteopenic or osteoporotic patients switching from ART including tenofovir disoproxil fumarate (TDF) and a ritonavir-boosted protease inhibitor (r/PI) to ART including RAL+r/PI.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Raltegravir
Intervention descriptions: intervention 1: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.

Protocol document: